After five years, Nido Biosciences has reached the end of the road, closing its doors after its lead neurological disease ...

Welcome to Fierce Biotech's fifth annual layoff tracker, a resource designed to keep pace with the sector's steady stream of ...

On the final trading day of 2025, Cathie Wood put an eye-brow raising $1.33 million to work in Intellia Therapeutics ( NTLA ) ...

Here is the full list of the biotech and pharma Startup Battlefield 200 selectees, along with a note on what made us select ...

Boston spent the past decade selling itself as the safest bet in science, a place where a doctorate was practically a ticket ...

Tucked inside a 3,000-page national defense bill signed into law last month is a set of new regulations that could upend the way local biotech companies do business. The Biosecure Act, as it is known, ...

XBI biotech ETF surged 65% as M&A heats up, but 2026 brings headwinds and tougher gains. Click here for a detailed analysis.

In the rapidly evolving landscape of modern biotechnology, the precision of molecular tools determines the speed of medical breakthroughs. As a Global Leading Biotinylated Peptide Synthesis specialist ...

Small and mid-cap biotech stocks entered 2025 like a compressed spring, and it finally snapped higher— here's why.

The new saw: Development-stage biotechs are maturing. Their drugs are winning approvals and independent commercial launches are starting to deliver meaningful revenue. The sector is turning profitable ...

According to Gartner, 58% of finance functions employed AI in 2024—a 21-percentage-point jump from the prior year. PwC ...

O4, Jared Holz of Mizuho joined ‘Power Lunch’ on CNBC to talk about how to play biotech moving into 2026. Holz noted that ...